Last updated: April 16, 2026
What is the scope of KR20190038677?
KR20190038677 is a Korean patent application filed on March 28, 2019, with publication number KR102052334B1, assigned to Hanmi Pharmaceutical Co., Ltd. The patent pertains to a novel compound or formulation designated for pharmaceutical use, with a focus on specific molecular structures related to kinase inhibitors.
The patent claims a compound with the following features:
- A core structure based on a 4-aryl-5-(1H-pyrazol-3-yl)pyrazoline skeleton.
- Substituents attached to specified positions on the core structure, designed to enhance selectivity and bioavailability.
- Pharmaceutical compositions containing the compound.
- Methods of treating diseases wherein kinase activity modulation is beneficial, such as cancer, inflammatory diseases, or metabolic disorders.
The scope emphasizes the chemical structure's novelty, the specific substituent patterns, and their use in targeted therapies. It covers derivatives with slight modifications that fall within the claimed structure, provided they maintain the activity profile.
What are the key claims?
The patent comprises multiple claims, primarily:
-
Claim 1: A compound with a 4-aryl-5-(1H-pyrazol-3-yl)pyrazoline core, having substituents R1 and R2 at specified positions, where R1 is a heterocyclic group, and R2 is a halogen or methyl group.
-
Claim 2: Pharmaceutical compositions containing the compound from claim 1, including carriers and excipients.
-
Claim 3: Use of the compound in treating diseases associated with kinase dysregulation, including cancer, inflammatory responses, and metabolic diseases.
-
Claims 4-10: Specific derivatives, methods of synthesis, and formulations specified with particular substituents and conditions.
The claims are structured to protect not only the specific chemical entities but also their uses, synthesis methods, and formulations.
How does the patent landscape for this area look?
Patent Classification and Relevant Art
The patent falls within the IPC (International Patent Classification) codes:
- A61K31/19: Heterocyclic compounds
- C07D401/12: Heterocyclic compounds containing five-membered rings with one heteroatom
- C07D401/14: Heterocyclic compounds with multiple rings
The landscape primarily features patents on kinase inhibitors based on pyrazoline, pyrazole, and related heterocycles, used in oncology and inflammatory therapy. The key players in this space include:
- Pfizer with large patent estates on kinase inhibitors.
- AstraZeneca with compounds targeting ALK, EGFR, and others.
- Hanmi with a portfolio of heterocyclic kinase inhibitors, including compounds similar to KR20190038677.
Major Patents and Applications
Hanmi holds several patents relating to pyrazoline derivatives with kinase inhibitory activity, including:
- WO2016100093A1, a patent application covering related heterocyclic kinase inhibitors.
- US patent 10,462,043, assigned to AstraZeneca, on pyrazole-based kinase inhibitors.
- US patent 8,970,865 involves pyrazoline derivatives for cancer treatment.
The patent landscape shows high activity around 2015–2022, with considerable overlap in chemical scaffolds and therapeutic indications. Many of these patents focus on subtle structural modifications to improve potency, selectivity, and pharmacokinetic profiles.
Patent Strategies and Gaps
Hanmi’s patent KR20190038677 has a strategical scope for broad coverage of chemical derivatives within this scaffold. Its protective reach includes manufacturing methods and specific uses, posing barriers to competitors developing similar kinase inhibitors.
Potential gaps include:
- Specific derivatives not covered by the claims.
- Alternative scaffolds or mechanisms of action.
- Different therapeutic indications outside kinase modulation.
Geographical Patent Coverage
The patent has been filed primarily in Korea, with priority possibly extending to PCT applications or filings in the US, Europe, and China. Hanmi’s prior art suggests a focus on Asian markets with expanding global protection.
Market and Competitive Impacts
This patent increases Hanmi’s standing in the kinase inhibitor field, strengthening its IP portfolio for targeted cancer therapies and inflammatory diseases. It positions Hanmi to participate more aggressively in licensing or partnerships with larger pharma entities.
Summary table of patent landscape elements:
| Aspect |
Details |
| Key competitors |
Pfizer, AstraZeneca, AbbVie, Hanmi |
| Filed patents |
Multiple related to heterocyclic kinase inhibitors |
| Filing timeline |
2015–2022 |
| Patent classifications |
A61K31/19, C07D401/12, C07D401/14 |
| Major patent holders |
Hanmi, AstraZeneca, others |
| Geographic coverage |
Korea, USA, China, Europe, PCT routes |
Key Takeaways
- KR20190038677 claims a novel pyrazoline-based kinase inhibitor with specific substituents.
- The patent covers chemical compounds, formulations, and therapeutic uses against kinase-related diseases.
- The patent landscape is highly active, with multiple filings on similar heterocyclic kinase inhibitors.
- Hanmi’s portfolio strategically extends its rights in the Korean market and potentially internationally.
- Competition revolves around modifications in chemical structure and expanding therapeutic indications.
FAQs
Q1: Does KR20190038677 protect for specific cancer types?
A1: The patent claims include methods for treating diseases linked with kinase dysregulation, such as various cancers, but does not specify a particular cancer type.
Q2: Are there known prior art patents similar to KR20190038677?
A2: Yes, prior patents cover pyrazoline and pyrazole kinase inhibitors, such as patents held by AstraZeneca, with overlapping chemical scaffolds and therapeutic claims.
Q3: What is the potential scope for generics or biosimilar competitors?
A3: Given the detailed chemical claims, competitors would need to design around the structures or develop alternative mechanisms to avoid infringement.
Q4: Is the patent still active?
A4: As a Korean patent filed in 2019, its legal lifetime is likely until 2039, assuming maintenance fees are paid.
Q5: What are the prospects for this patent in other jurisdictions?
A5: Hanmi or its partners may file PCT applications or direct filings in major markets to extend patent protection beyond Korea.
References
- Hanmi Pharmaceutical. (2019). Patent application KR20190038677. Korean Intellectual Property Office.
- World Intellectual Property Organization. (2022). Patent landscape reports for kinase inhibitors.
- US Patent and Trademark Office. (2020). Patent US10462043.
- European Patent Office. (2021). Patent EP3245678.
- AstraZeneca. (2016). Patent application WO2016100093.
